MX363380B - Formulacion de anticuerpos. - Google Patents
Formulacion de anticuerpos.Info
- Publication number
- MX363380B MX363380B MX2014015262A MX2014015262A MX363380B MX 363380 B MX363380 B MX 363380B MX 2014015262 A MX2014015262 A MX 2014015262A MX 2014015262 A MX2014015262 A MX 2014015262A MX 363380 B MX363380 B MX 363380B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody formulation
- antibody
- sugars
- formulated
- surfactant
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261658472P | 2012-06-12 | 2012-06-12 | |
| PCT/IB2013/054777 WO2013186700A1 (en) | 2012-06-12 | 2013-06-11 | Antibody formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014015262A MX2014015262A (es) | 2015-06-23 |
| MX363380B true MX363380B (es) | 2019-03-21 |
Family
ID=48914378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014015262A MX363380B (es) | 2012-06-12 | 2013-06-11 | Formulacion de anticuerpos. |
Country Status (35)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2521568T3 (pl) | 2010-01-06 | 2019-03-29 | Dyax Corp. | Białka wiążące kalikreinę osocza |
| WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| KR102502293B1 (ko) | 2011-01-06 | 2023-02-21 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| CA2906624A1 (en) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| CN104730237A (zh) * | 2013-12-23 | 2015-06-24 | 国家纳米科学中心 | 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法 |
| JP6845012B2 (ja) | 2014-01-21 | 2021-03-17 | ダイアックス コーポレーション | 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用 |
| EP3116911B8 (en) | 2014-03-12 | 2019-10-23 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| US10059761B2 (en) | 2014-03-12 | 2018-08-28 | Prothena Biosciences Limited | Anti-Laminin4 antibodies specific for LG4-5 |
| KR20230109785A (ko) | 2014-03-27 | 2023-07-20 | 다케다 파머수티컬 컴패니 리미티드 | 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법 |
| KR101597037B1 (ko) | 2014-06-26 | 2016-02-24 | 엘지디스플레이 주식회사 | 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치 |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| IL254292B1 (en) * | 2015-03-30 | 2025-09-01 | Dyax Corp | Plasma kallikrein inhibitors and their uses for preventing the onset of hereditary angioedema |
| EP3350226A2 (en) * | 2015-09-16 | 2018-07-25 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| BR112018010211A2 (pt) * | 2015-12-07 | 2019-02-05 | Merck Patent Gmbh | formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab |
| WO2017100679A1 (en) | 2015-12-11 | 2017-06-15 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| JP6897570B2 (ja) * | 2015-12-18 | 2021-06-30 | アステラス製薬株式会社 | 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物 |
| AU2017286375B2 (en) * | 2016-06-16 | 2019-04-18 | Janssen Vaccines & Prevention B.V. | HIV vaccine formulation |
| CA3041254A1 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
| KR102312222B1 (ko) | 2016-12-22 | 2021-10-12 | 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 | Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체 |
| AU2018227036B2 (en) * | 2017-03-01 | 2021-07-08 | Medimmune Limited | Formulations of monoclonal antibodies |
| UA129583C2 (uk) * | 2017-03-06 | 2025-06-11 | Мерк Патент Гмбх | Водний фармацевтичний склад, який містить антитіло проти pd-l1 авелумаб |
| EP3612217A4 (en) * | 2017-04-18 | 2020-12-30 | Dr. Reddy's Laboratories Limited | STABLE LIQUID PHARMACEUTICAL COMPOSITION |
| PT3658184T (pt) * | 2017-07-27 | 2023-11-29 | Alexion Pharma Inc | Formulações de anticorpo anti-c5 de elevada concentração |
| EP4233901A3 (en) * | 2017-08-22 | 2023-09-06 | Biogen MA Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| CN111757730A (zh) | 2017-10-06 | 2020-10-09 | 普罗塞纳生物科学有限公司 | 检测甲状腺素运载蛋白的方法 |
| BR112020010483A2 (pt) * | 2017-11-29 | 2020-10-20 | Prothena Biosciences Limited | formulação liofilizada de um anticorpo monoclonal contra transtirretina |
| IL322895A (en) | 2018-06-05 | 2025-10-01 | King S College London | Btnl3/8-targeted constructs for delivery of cargo to the digestive system |
| EP3814373A1 (en) | 2018-06-28 | 2021-05-05 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| KR20210106476A (ko) | 2018-12-18 | 2021-08-30 | 노파르티스 아게 | 고농도의 항-vegf 항체를 함유하는 단백질 용액 제형 |
| JP7266108B2 (ja) | 2019-02-18 | 2023-04-27 | イーライ リリー アンド カンパニー | 治療用抗体製剤 |
| WO2020173431A2 (zh) * | 2019-02-26 | 2020-09-03 | 信达生物制药(苏州)有限公司 | 包含抗cd47抗体的制剂及其制备方法和用途 |
| WO2021091706A1 (en) | 2019-11-06 | 2021-05-14 | Novartis Ag | Treatment for sjögren's syndrome |
| CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| CA3168600A1 (en) * | 2020-01-21 | 2021-07-29 | Innovent Biologics (Suzhou) Co., Ltd. | Recombinant fully human anti-tigit monoclonal antibody formulation, method for preparing same and use thereof |
| WO2022031568A1 (en) * | 2020-08-04 | 2022-02-10 | Novartis Ag | Treatment of cll |
| CA3190678A1 (en) * | 2020-08-04 | 2022-02-10 | Novartis Ag | Treatment of b cell malignancies |
| JP2023553641A (ja) * | 2020-12-17 | 2023-12-25 | アストラゼネカ アクチボラグ | 抗ｉｌ５ｒ抗体製剤 |
| CN115073598B (zh) * | 2021-03-15 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗baffr抗体及其应用 |
| CA3215919A1 (en) | 2021-05-04 | 2022-11-10 | Novartis Ag | Treatment for systemic lupus erythematosus using anti-baffr antibodies |
| US20240239911A1 (en) | 2021-05-04 | 2024-07-18 | Novartis Ag | Treatment for lupus nephritis using anti-baffr antibodies |
| KR20240069787A (ko) * | 2021-09-29 | 2024-05-20 | 드래곤플라이 쎄라퓨틱스, 인크. | 항체 표적화 baff-r 및 이의 사용 |
| WO2024102675A1 (en) | 2022-11-07 | 2024-05-16 | Upstream Bio, Inc. | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| CN118681009A (zh) * | 2023-03-21 | 2024-09-24 | 百奥泰生物制药股份有限公司 | 一种复方制剂及其应用 |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
| WO2025257781A1 (en) * | 2024-06-14 | 2025-12-18 | Novartis Ag | Treatment of systemic sclerosis using anti-baff-r antibodies |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| JP2003530899A (ja) | 1999-06-23 | 2003-10-21 | オレゴン ヘルス アンド サイエンス ユニバーシティー | 造血を増強する方法 |
| DE60114830T2 (de) | 2000-06-28 | 2006-08-03 | Glycofi, Inc. | Verfahren zur herstellung modifizierter glycoproteine |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| EP1441589B1 (en) | 2001-11-08 | 2012-05-09 | Abbott Biotherapeutics Corp. | Stable liquid pharmaceutical formulation of igg antibodies |
| EP1946776B1 (en) | 2002-02-27 | 2017-01-18 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| WO2004055164A2 (en) | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| MX2007008017A (es) * | 2004-12-31 | 2007-09-12 | Genentech Inc | Polipeptidos que se ligan a br3 y usos de los mismos. |
| RS54299B1 (sr) * | 2008-07-17 | 2016-02-29 | Novartis Ag | Sastavi i metode upotrebe terapijskih antitela |
| KR101614983B1 (ko) * | 2009-11-17 | 2016-04-22 | 입센 파마 에스.에이.에스 | Ｈｇｈ 및 ｒｈｉｇｆ―１의 조합물을 위한 제제 |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| WO2013083497A1 (en) | 2011-12-06 | 2013-06-13 | F. Hoffmann-La Roche Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
-
2013
- 2013-06-07 US US13/912,355 patent/US9216219B2/en active Active
- 2013-06-10 MA MA37616A patent/MA37616A1/fr unknown
- 2013-06-11 LT LT13744818T patent/LT2858671T/lt unknown
- 2013-06-11 HU HUE13744818A patent/HUE045523T2/hu unknown
- 2013-06-11 MY MYPI2014703690A patent/MY179818A/en unknown
- 2013-06-11 AU AU2013276112A patent/AU2013276112B2/en active Active
- 2013-06-11 MX MX2014015262A patent/MX363380B/es unknown
- 2013-06-11 EP EP13744818.9A patent/EP2858671B1/en active Active
- 2013-06-11 SI SI201331596T patent/SI2858671T1/sl unknown
- 2013-06-11 PL PL13744818T patent/PL2858671T3/pl unknown
- 2013-06-11 ES ES13744818T patent/ES2751659T3/es active Active
- 2013-06-11 HR HRP20191827TT patent/HRP20191827T1/hr unknown
- 2013-06-11 WO PCT/IB2013/054777 patent/WO2013186700A1/en not_active Ceased
- 2013-06-11 PT PT137448189T patent/PT2858671T/pt unknown
- 2013-06-11 JP JP2015516723A patent/JP6265978B2/ja active Active
- 2013-06-11 CN CN201380031181.8A patent/CN104363920B/zh active Active
- 2013-06-11 TW TW102120795A patent/TWI653983B/zh active
- 2013-06-11 CA CA2875386A patent/CA2875386C/en active Active
- 2013-06-11 PE PE2014002437A patent/PE20150200A1/es not_active Application Discontinuation
- 2013-06-11 BR BR112014030820-9A patent/BR112014030820B1/pt active IP Right Grant
- 2013-06-11 EP EP19185836.4A patent/EP3593814A1/en active Pending
- 2013-06-11 KR KR1020157000336A patent/KR102124820B1/ko active Active
- 2013-06-11 NZ NZ630885A patent/NZ630885A/en not_active IP Right Cessation
- 2013-06-11 SG SG11201408174UA patent/SG11201408174UA/en unknown
- 2013-06-11 EA EA201492292A patent/EA033373B1/ru not_active IP Right Cessation
- 2013-06-11 DK DK13744818.9T patent/DK2858671T3/da active
- 2013-06-12 AR ARP130102057 patent/AR091413A1/es not_active Application Discontinuation
-
2014
- 2014-11-20 ZA ZA2014/08547A patent/ZA201408547B/en unknown
- 2014-11-21 TN TN2014000488A patent/TN2014000488A1/fr unknown
- 2014-11-27 IL IL235966A patent/IL235966B/en active IP Right Grant
- 2014-12-11 PH PH12014502778A patent/PH12014502778A1/en unknown
- 2014-12-11 GT GT201400285A patent/GT201400285A/es unknown
- 2014-12-11 CL CL2014003370A patent/CL2014003370A1/es unknown
- 2014-12-18 CO CO14278419A patent/CO7151487A2/es unknown
-
2015
- 2015-01-12 EC ECIEPI201517314A patent/ECSP15017314A/es unknown
- 2015-11-16 US US14/942,388 patent/US9751951B2/en active Active
-
2017
- 2017-08-31 US US15/692,490 patent/US20180051092A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/980,411 patent/US10689451B2/en active Active
-
2019
- 2019-10-22 CY CY20191101096T patent/CY1122181T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502778A1 (en) | Antibody formulation | |
| TN2014000431A1 (en) | Antibody formulatoin | |
| WO2012076670A3 (en) | Antibody formulation | |
| PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| PH12015502441B1 (en) | Anti-il-4/anti-il-13 bispecific antibody formulations | |
| PE20160681A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
| UA110979C2 (uk) | Рідка фармацевтична композиція, яка включає нітизинон | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| AR130115A2 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| WO2013127539A3 (de) | Pharmazeutische formulierung enthaltend flupirtin | |
| TR201203086A2 (tr) | Sefiksim ve klavulanik asit içeren farmasötik dozaj formu. | |
| TH175929A (th) | สูตรตำรับของแอนติบอดี้ (Antibody Formulation) | |
| TR201203083A2 (tr) | Sefdinir ve klavulanik asit içeren farmasötik dozaj formu. | |
| TR201203084A2 (tr) | Sefditoren pivoksil ve klavulanik asit içeren formülasyonlar. | |
| TR201203085A2 (tr) | Sefetamet ve klavulanik asit içeren bileşimler. |